By Tracy Cabrera
A CORONAVIRUS vaccine being developed by a team led by an Irish scientist at Oxford University could be ready by as early as September as all test subjects under trials by Irish scientist Adrian Hill have all produced antibodies found in patients who have contracted the virus and recovered from it.
Hill, who has previously worked on Ebola and malaria vaccines, has been leading a team of researchers at the famous English university to find a vaccine for Covid-19 since May and human trials have gone extremely well, according to numerous reports.
In total, thousands of Britons have been recruited for the research during phase one of the vaccine development.
The Daily Telegraph reports that the vaccine potentially offers ‘double protection’ against the virus, with volunteers’ blood samples showing an accelerated growth in antibodies and T-cells, both of which play a vital role in the body’s response to Covid-19.
The Guardian additionally reports that multinational pharmaceutical company AstraZeneca has agreed to supply 100 million doses of the Oxford vaccine in Britain and a further 300 million doses in the United States. The pharmaceutical company is slated to begin distributing the vaccine in September or October.
The Oxford vaccine team now plans to move to a human ‘challenge trial’, where subjects will be intentionally exposed to the virus.
In human challenge trials, volunteers are given a dose of the vaccine and then intentionally exposed to the virus to test the efficacy of the vaccine. In conventional efficacy trials, volunteers resume life and wait to contract the virus, meaning that the challenge trials could potentially speed up the development of a vaccine.
Human challenge trials are considered controversial in the context of Covid-19 since there is no known cure for the virus, but Adrian Hill argues that the risk level is very low since the test subjects will all be in their 20s.
Recent research has found that the mortality rate from Covid-19 for someone in their 20s is around one in every 3,000 and Hill, along with a growing number of prominent scientists, argues that the risk is offset by the global impact of the deadly disease.
The challenge trials are set to be run in conjunction with phase three of the vaccine trials, when volunteers would be exposed to the coronavirus in everyday life.
Hill argues that challenge trials could be used to speed up the process and to provide additional information about the vaccine.
“If challenge trials can safely and effectively speed the vaccine development process, there is a formidable presumption in favor of their use, which would require a very compelling ethical justification to overcome,: the Irish scientist pointed out.